SCHEMBL7989780

SCHEMBL7989780

CC(C)(C)C(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.74
HSD17B1 P14061 3/20 0.73
LMNA P02545 2/20 0.73
MAPT P10636 2/20 0.73
RECQL P46063 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
STS P08842 10/20 0.71
ABCC4 O15439 1/20 0.71
CYP2C9 P11712 1/20 0.71
ABCC1 P33527 1/20 0.71
SLCO1B1 Q9Y6L6 1/20 0.71
KDM4E B2RXH2 2/20 0.70
ALDH1A1 P00352 1/20 0.70
CA1 P00915 3/20 0.68
CA2 P00918 3/20 0.68
CA9 Q16790 3/20 0.68
ESR1 P03372 2/20 0.68
ESR2 Q92731 2/20 0.68
CA4 P22748 1/20 0.68
CA6 P23280 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27592877 0.91 CYP3A4 (0.72) CYP3A4HSD17B1LMNAMAPTRECQL
Estrone Acetate SCHEMBL603954 0.89 CYP3A4 (0.76) CYP3A4HSD17B1LMNAMAPTRECQL
SCHEMBL1977541 0.89 CYP3A4 (0.80) CYP3A4HSD17B1LMNAMAPTRECQL
Estrone Acetate SCHEMBL20006536 0.89 CYP3A4 (0.76) CYP3A4HSD17B1LMNAMAPTRECQL
Estrone Acetate SCHEMBL6241050 0.89 CYP3A4 (0.76) CYP3A4HSD17B1LMNAMAPTRECQL
SCHEMBL12216745 0.88 CYP3A4 (0.75) CYP3A4HSD17B1LMNAMAPTRECQL
SCHEMBL9790047 0.88 CYP3A4 (0.74) CYP3A4HSD17B1LMNAMAPTRECQL
SCHEMBL7992527 0.87 CYP3A4 (0.72) CYP3A4HSD17B1LMNAMAPTRECQL
SCHEMBL26659868 0.86 CYP3A4 (0.75) CYP3A4HSD17B1LMNAMAPTRECQL
SCHEMBL10013342 0.86 HSD17B1 (0.78) CYP3A4HSD17B1LMNAMAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279170-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF KANSAS STATE UNIVERSITY RESEARCH FOUNDATION 2023-09-07 US claimed
US-20230279170-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF KANSAS STATE UNIVERSITY RESEARCH FOUNDATION 2023-09-07 US disclosed
US-20220204447-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS NATIONAL SCIENCE FOUNDATION 2022-06-30 US disclosed
US-10961266-B2 Chemoselective methylene hydroxylation in aromatic molecules THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2021-03-30 US disclosed
US-10772878-B2 Demethylpenclomedine analogs and their use as anti-cancer agents DEKK-TEC, INC. (US) 2020-09-15 US disclosed
WO-2020163295-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) 2020-08-13 WO disclosed
US-20200087331-A1 CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2020-03-19 US disclosed
US-9422241-B2 Demethylpenclomedine analogs and their use as anti-cancer agents DEKK-TEC, INC. (US) 2016-08-23 US disclosed
US-20160074853-A1 LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2016-03-17 US disclosed
US-20120177634-A1 DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS DEKK-TEC, INC. 2012-07-12 US disclosed
US-6274118-B1 INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE NORDION INTERNATIONAL INC. (CA) 2001-08-14 US disclosed
WO-1995002424-A1 LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN NORDION INTERNATIONAL INC. (CA) 1995-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160074853-A1 LIGAND, NICKEL COMPLEX COMPRISING THE LIGAND, AND REACTION USING THE NICKEL COMPLEX NISCH, DDT, TEC CYP3A4 902/4885HSD17B1 2577/4885LMNA 4621/4885
US-20220204447-A1 CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF IN ASYMMETRIC OXIDATION REACTIONS DHPS, PCBP1, PNKP CYP3A4 24/4885HSD17B1 849/4885LMNA 3416/4885
US-10961266-B2 Chemoselective methylene hydroxylation in aromatic molecules PAH, DBH, AHR CYP3A4 29/4885HSD17B1 1517/4885LMNA 4444/4885
US-20200087331-A1 CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES PAH, DBH, AHR CYP3A4 29/4885HSD17B1 1517/4885LMNA 4444/4885
US-10772878-B2 Demethylpenclomedine analogs and their use as anti-cancer agents MCL1, DNMT1, MYC CYP3A4 3548/4885HSD17B1 2345/4885LMNA 1636/4885
US-20120177634-A1 DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS MCL1, DNMT1, MYC CYP3A4 3548/4885HSD17B1 2345/4885LMNA 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.